-
Mashup Score: 1Research Efforts Seek to Unlock the Potential of PARP Inhibition in Thoracic Malignancies - 3 year(s) ago
Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Research Efforts Seek to Unlock the Potential of PARP Inhibition in Thoracic Malignancies - 3 year(s) ago
Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0KRAS Inhibitors Reach New Milestones in NSCLC - 3 year(s) ago
Significant advances have been made regarding the development of KRAS G12C inhibitors in non–small cell lung cancer in recent years, explained Karen L. Reckamp, MD, who added that research regarding predictive co-mutations, acquired resistance, and combination strategies is expected to propel the utility of these agents even further.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3GO2 Foundation for Lung Cancer to Honor Heather Wakelee, M.D. with the 2021 Bonnie J. Addario Lectureship Award | GO2 Foundation for Lung Cancer - 3 year(s) ago
GO2 Foundation recognizes Dr. Wakelee, president elect of IASLC, for her leadership on lung cancer clinical trials and research.
Source: GO2 Foundation for Lung CancerCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0Bispecifics Prove to Have Intriguing Role in Lung Cancer - 3 year(s) ago
Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0New Strategies for RET Inhibition May Expand Their Role in NSCLC - 3 year(s) ago
RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors @PatelOncology @UCSDHealth @gotoPER #ILCC2021 #lcsm https://t.co/PUEfLIQ0FG